By Nancy Lapid
(Reuters) – The next is a abstract of some latest research on COVID-19. They embrace analysis that warrants additional research to corroborate the findings and that has but to be licensed by peer evaluation.
Some lengthy COVID sufferers nonetheless have virus in blood
Some circumstances of lengthy COVID stands out as the immune system’s response to a SARS-CoV-2 an infection lurking someplace within the physique, new findings from a small research recommend.
Researchers analyzed a number of plasma samples collected over time from 63 sufferers with COVID-19, together with 37 who went on to develop lengthy COVID. Within the majority of these with lengthy COVID, the spike protein from the floor of the virus was detectable for as much as 12 months, whereas it was not current in plasma samples from recovered sufferers with out signs. Spike protein circulating within the blood may imply “a reservoir of lively virus persists within the physique,” the researchers stated in a paper posted on medRxiv https://www.medrxiv.org/content material/10.1101/2022.06.14.22276401v1 final week forward of peer evaluation. Precisely the place that reservoir may be not clear from this research. Researchers stated they’d beforehand discovered lively virus within the gastrointestinal tract of kids weeks after the preliminary coronavirus an infection, and different researchers have discovered genetic proof of the virus “in a number of anatomical websites as much as seven months after symptom onset.”
If the outcomes may be confirmed in bigger research, the presence of spike protein within the blood lengthy after the preliminary an infection could also be one approach to diagnose lengthy COVID, the researchers stated.
Paxlovid “rebound” sufferers may have longer therapy
The rebound of signs reported in some COVID-19 sufferers who took a five-day course of Pfizer’s antiviral Paxlovid capsules could also be the results of inadequate therapy, in accordance with researchers who intently evaluated one such affected person.
Trial outcomes confirmed that Paxlovid can cut back the chance of hospitalization and loss of life from COVID-19 in high-risk sufferers by 89% if taken inside 5 days of symptom onset. In some sufferers, nevertheless, virus ranges and signs have rebounded after finishing a course of Paxlovid, resulting in issues that variants may be growing resistance to the two-drug therapy or that the capsules might by some means be weakening sufferers’ antibody resistance. However when researchers remoted the Omicron BA.2 variant from a rebound affected person and examined it in lab experiments, they discovered it was nonetheless delicate to Paxlovid and had no mutations that would scale back the drug’s effectiveness. In addition they discovered their affected person’s antibodies may nonetheless block the virus from getting into and infecting new cells.
The rebound of COVID-19 signs after Paxlovid therapy is probably going occurring as a result of not sufficient of the drug is reaching contaminated cells to fully cease the virus from making copies of itself, the researchers stated in a paper revealed on Monday in Medical Infectious Ailments https:/ /educational.oup.com/cid/advance-article/doi/10.1093/cid/ciac496/6611663. It’s also attainable that the drug could also be metabolized, or processed, at completely different charges in numerous individuals, or that some individuals must take it for greater than 5 days.
After COVID-19, children have extra signs however much less nervousness
Persistent well being issues had been solely barely extra widespread in youngsters after COVID-19 than in similarly-aged children who averted the virus, researchers from Denmark reported on Wednesday in The Lancet Youngster & Adolescent Well being https://www.thelancet.com/journals/ lanchi/article/PIIS2352-4642(22)00154-7/fulltext. Anxiousness ranges, nevertheless, had been increased in youngsters who by no means had COVID-19, the researchers additionally discovered.
They stated 40% of infants and toddlers with COVID-19 and 27% of their uninfected friends skilled at the very least one symptom for greater than two months. Amongst children ages 4 to 11, persistent signs had been seen in 38% with COVID-19 and 34% with out it. And amongst 12- to 14-year-olds, 46% of these with COVID-19 and 41% of these with out it had long-lasting signs. The outcomes had been based mostly on a survey of practically 11,000 moms of contaminated youngsters and practically 33,000 moms of uninfected youngsters.
Whereas signs related to lengthy COVID resembling headache, temper swings, belly ache and fatigue are sometimes skilled by in any other case wholesome youngsters, contaminated youngsters had longer-lasting signs and one-third had new signs that developed after COVID-19. To the researchers’ shock, youngsters who had COVID-19 skilled fewer psychological and social issues than these within the management group. They speculated this can be as a result of the uninfected youngsters had extra “concern of the unknown illness and extra restricted on a regular basis life resulting from defending themselves from catching the virus.”
Click on for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in growth.
(Reporting by Nancy Lapid; Modifying by Invoice Berkrot)